Recent studies demonstrate that modulating LAMTOR1 enhances immunotherapy efficacy in NSCLC by reducing exosomal PD-L1 [44] and synergizes with chemotherapy via cGAS-STING activation [28]. Here, LAMTOR1 is linked to non-small cell lung carcinoma.